Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer
James W Denham, Michael Nowitz, David Joseph, Gillian Duchesne, Nigel A Spry, David S Lamb, John Matthews, Sandra Turner, Chris Atkinson, Keen-Hun Tai, Nirdosh Kumar Gogna, Lizbeth Kenny, Terry Diamond, Richard Smart, David Rowan, Pablo Moscato, Renato Vimieiro, Richard Woodfield, Kevin Lynch, Brett Delahunt Show all
BJU International | WILEY-BLACKWELL | Published : 2014
This study was funded by the National Health and Medical Research Council (Canberra, ACT, Australia), Novartis Pharmaceuticals, Abbott Pharmaceuticals (both Sydney, NSW, Australia), New Zealand Health Research Council, New Zealand Cancer Society, University of Newcastle (Australia), Hunter Medical Research Institute (New Lambton Heights, NSW, Australia) Calvary Mater Radiation Oncology Fund (Waratah, NSW, Australia), and Maitland Cancel Appeal (Rutherford, NSW, Australia). We thank Rosemary Bradford (Prostate Cancer Trials Group, University of Newcastle) for her skilful preparation of the report.